Epizyme (EPZM) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom forecasts quarterly sales below estimates amid rising custom AI chip competition
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
Epizyme (EPZM) PT Lowered to $19 at RBC Capital; Reiterates Outperform
March 9, 2017 1:20 PM ESTRBC Capital lowered its price target on Epizyme (NASDAQ: EPZM) to $19.00 (from $26.00) while maintaining a Outperform rating. Epizyme provided a development update and discussed its current understanding of tazemetostats mechanism of action .
Analyst Simos Simeonidis commented, "Epizyme provided a development update on... More
